Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey
Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey
复制标题
DOI：
10.1038/bmt.2016.18
复制
发表时间：
2016-06-01
影响因子：
4.8
通讯作者：
Gratwohl, A.
中科院分区：
文献类型：
--
作者：
Niederwieser, D.;Baldomero, H.;Gratwohl, A.
对来自77个国家和地区的1566个团队收集并通过地区移植组织报告的68 146例造血干细胞移植(HSCT)(53%为自体，47%为异体)的数据进行了2012年主要适应症、供体类型和干细胞来源的分析。每1000万居民的移植比率从0.1到1001不等，来自无血缘关系的16 433名捐赠者登记的造血干细胞移植比相关的15 493名捐赠者多。移植物来自外周血(66%)、骨髓(24%；主要是非恶性疾病)和脐带血(10%)。与2006年相比，总数增加了46%(57%是同种异体，38%是自体)。增长是由于报告团队(18%)和移植活动中位数/团队(从38个到48个/团队)的增加。在错配/单倍体相合的家系中，HSCT发生率增加了167%。优势、劣势、机会、威胁(SWOT)分析揭示了WBMT的全球视野是其主要优势，并确定了其成为患者和当局关键专业机构的潜力。有限的数据收集仍然是它的主要弱点和威胁。总而言之，多年来，全球HSCT在世界卫生组织的四个地区以不同的速度增长，而没有停滞不前(异基因和自体)。在同种异体、半相合的HSCT中观察到了主要的增加，在脐带血移植中也有较小程度的增加。
Data on 68 146 hematopoietic stem cell transplants (HSCTs) (53% autologous and 47% allogeneic) gathered by 1566 teams from 77 countries and reported through their regional transplant organizations were analyzed by main indication, donor type and stem cell source for the year 2012. With transplant rates ranging from 0.1 to 1001 per 10 million inhabitants, more HSCTs were registered from unrelated 16 433 donors than related 15 493 donors. Grafts were collected from peripheral blood (66%), bone marrow (24%; mainly non-malignant disorders) and cord blood (10%). Compared with 2006, an increase of 46% total (57% allogeneic and 38% autologous) was observed. Growth was due to an increase in reporting teams (18%) and median transplant activity/team (from 38 to 48 HSCTs/team). An increase of 167% was noted in mismatched/haploidentical family HSCT. A Strengths, Weaknesses, Opportunities, Threats (SWOT) analysis revealed the global perspective of WBMT to be its major strength and identified potential to be the key professional body for patients and authorities. The limited data collection remains its major weakness and threat. In conclusion, global HSCT grows over the years without plateauing (allogeneic>autologous) and at different rates in the four World Health Organization regions. Major increases were observed in allogeneic, haploidentical HSCT and, to a lesser extent, in cord blood transplantation.